Lisa M. Bruneau

Background

About Lisa M. Bruneau

A seasoned hands-on, roll-up-your-sleeves financial executive with over twenty+ years of progressive responsibilities in the life sciences industry across all financial operations from private to public to commercial companies, and have an MBA in International Business. A partner to the business with strong business acumen and the ability to translate the business story into a clear and concise financial picture for multiple stakeholders. Collaborative, entrepreneurial, perseverant, transparent, empathetic, a strategic thinker and problem solver, innately curious, and detailed and process-oriented. Self-directed and able to multi-task, manage through change, and lead in a fast-paced environment. Dedicated and passionate about being part of the team to help companies develop transformative medicines that improve the lives of patients and their families. Executive-level team player IPOs (2), numerous equity/debt financings (~$1B) Financial closings and reporting M&A experience (2 acquisitions, 2 reverse mergers) External audit and SEC reporting Commercial launch experience (FOTIVDA®) Internal controls and SOX compliance "Big Pharma" partnerships (AZ, GSK, Roche, Sanofi) Budgeting, forecasting, LRP, cash management Phase 1-3 clinical trial life-cycle management Business process development AVEO Key Highlights: Key player in both AVEO’s transition to a commercial company upon the FDA market approval of FOTIVDA® (tivozanib) in March 2021 for advanced renal cell carcinoma and in AVEO’s acquisition in January 2023 by LG Chem, an affiliate of LG Corporation based in Seoul South Korea, including leading the financial due diligence. Led budgeting, forecasting, and long-range planning in close collaboration with the Executive Leadership Team. Partnered with the CFO/CEO to prepare and present presentations for Board meetings. Synta Key Highlights: Key player in Synta’s IPO and ultimate reverse merger with Madrigral Pharmaceuticals. Led Company-wide R&D budgeting and forecasting across multiple drug candidates and indications. Responsible for the financial management of corporate partnerships with GlaxoSmithKline and Roche.